In addition, the increase in PD-L1 expression and decrease in the phosphorylation of LDHA suggest that, if similar changes occur in vivo, sunitinib resistance may affect the ccRCC tumor microenvironment by becoming more immunosuppressive and less glycolytic. Here, CD274 is linked to neoplasm.